Immunoblastic morphology but not the immunohistochemical GCB/non-GCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL Running title: OUTCOME PREDICTION IN DLBCL
نویسندگان
چکیده
German Ott, Marita Ziepert, Wolfram Klapper, Heike Horn, Monika Szczepanowski, Heinz-Wolfram Bernd, Christoph Thorns, Alfred C. Feller, Dido Lenze, Michael Hummel, Harald Stein, Hans-Konrad Müller-Hermelink, Matthias Frank, Martin-Leo Hansmann, Thomas F. E. Barth, Peter Möller, Sergio Cogliatti, Michael Pfreundschuh, Norbert Schmitz, Lorenz Trümper, Markus Loeffler, Andreas Rosenwald for the DSHNHL
منابع مشابه
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.
The survival of diffuse large B-cell lymphoma patients varies considerably, reflecting the molecular diversity of tumors. In view of the controversy whether cytologic features, immunohistochemical markers or gene expression signatures may capture this molecular diversity, we investigated which features provide prognostic information in a prospective trial in the R-CHOP treatment era. Within the...
متن کاملLYMPHOID NEOPLASIA Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL
German Ott,1,2 Marita Ziepert,3 Wolfram Klapper,4 Heike Horn,2 Monika Szczepanowski,4 Heinz-Wolfram Bernd,5 Christoph Thorns,5 Alfred C. Feller,5 Dido Lenze,6 Michael Hummel,6 Harald Stein,6 Hans-Konrad Müller-Hermelink,1 Matthias Frank,7 Martin-Leo Hansmann,7 Thomas F. E. Barth,8 Peter Möller,8 Sergio Cogliatti,9 Michael Pfreundschuh,10 Norbert Schmitz,11 Lorenz Trümper,12 Markus Loeffler,3 an...
متن کاملMYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
MYC rearrangements occur in 5% to 10% of diffuse large B-cell lymphomas (DLBCL) and confer an increased risk to cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (CHOP) and rituximab (R)-CHOP treated patients. We investigated the prognostic relevance of MYC-, BCL2- and BCL6-rearrangements and protein expression in a prospective randomized trial. Paraffin-embedded tumor samples from...
متن کاملLenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysis.
Lenalidomide has been shown to produce durable responses in patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL). In order to gain better understanding of the efficacy of lenalidomide and compared the difference in clinical outcome between two subtypes of DLBCL. Seven eligible trials involving 375 adult patients were included in this meta-analysis. The patients in non-germ...
متن کاملClinicopathological Analysis of 320 Cases of Diffuse Large B-cell Lymphoma Using the Hans Classifier.
The estimation of clinical prognosis for diffuse large B-cell lymphoma (DLBCL) with a quick, cost-efficient method is necessary because of the clinical heterogeneity of this disease, which leads to death, relapsed or refractory disease in approximately 40% of patients. We analyzed 320 cases diagnosed from 2007 to 2013 treated with R-CHOP therapy at Tokai University Hospital and associated insti...
متن کامل